RecruitingNot ApplicableNCT05514405

Effect of Remimazolam and Propofol on Postoperative Delirium

Effect of Remimazolam and Propofol on Postoperative Delirium in Elderly Patients Undergoing Hip and Knee Surgery


Sponsor

Inje University

Enrollment

82 participants

Start Date

Aug 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Remimazolam is an ultra-short acting benzodiazepine agonist which is used widely for general anesthesia and sedation. Remimazolam has several advantages. Remimazolam is rapidly metabolized by tissue esterase that it does not accumulate even after infusion for long periods of time. The presence of reversal agents (flumazenil) is also advantageous. Also, hemodynamic stability compared to propofol gives clinicians preference to use for geriatric anesthesia. However, the study on the effect of remimazolam compared to propofol on postoperative delirium have not been carried out. The purpose of the study is to compare the incidence of postoperative delirium and recovery profile in elderly patients undergoing orthopedic surgery using either remimazolam or propofol.


Eligibility

Min Age: 65 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Propofol and a drug called Remimazolam (Byfavo) for people with hip fractures, knee osteoarthritis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 65 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRemimazolam (Byfavo)

Remimazolam is continuously infused based on bispectral index (within 40-60).

DRUGPropofol

Propofol is continuously infused based on bispectral index (within 40-60).


Locations(1)

Sanggye Paik hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05514405


Related Trials